Welcome to our dedicated page for NEOS news (Ticker: NEOS), a resource for investors and traders seeking the latest updates and insights on NEOS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NEOS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NEOS's position in the market.
Aytu BioScience and Neos Therapeutics have scheduled special meetings for stockholders regarding their proposed merger on March 18, 2021. Stockholders of record as of February 5, 2021 are eligible to vote. Upon merger completion, the combined entity will be named Aytu Biopharma and will continue trading under the stock symbol AYTU. Both companies' boards encourage stockholders to vote in favor of the proposals. The joint proxy statement/prospectus will be mailed to stockholders around February 12, 2021.
Aytu BioScience (NASDAQ:AYTU) and Neos Therapeutics (NASDAQ:NEOS) have scheduled special stockholder meetings for March 18, 2021, to discuss their proposed merger. The record date for eligibility to vote is February 5, 2021. Upon closing, the new entity will be rebranded as Aytu Biopharma, Inc., and will retain the AYTU ticker symbol on Nasdaq. Both companies’ Boards recommend stockholders vote 'FOR' the merger proposals. The joint proxy statement/prospectus will be mailed on February 12, 2021, providing further details on the merger process.
Neos Therapeutics, a pharmaceutical company focused on central nervous system products, announced that CEO Jerry McLaughlin will take part in a pre-recorded presentation at the H.C. Wainwright Virtual BioConnect Conference. This presentation will be accessible on the company's Investor Relations page starting January 11, 2021, at 6:00 a.m. ET, with a replay available for 30 days. Neos markets various ADHD treatments, including Adzenys XR-ODT and Cotempla XR-ODT, and is developing NT0502 for sialorrhea in neurological patients.
Aytu BioScience and Neos Therapeutics announced a definitive merger agreement, creating a combined entity valued at approximately $44.9 million. Neos shareholders will receive 0.1088 shares of Aytu for each of their shares. The merger aims to tap into the $8.5 billion ADHD market, with Neos contributing $57 million in revenues for the past year. Estimated annualized cost synergies of $15 million are expected to begin in fiscal year 2022. The merger is subject to shareholder approval and is anticipated to close by Q2 2021.
Neos Therapeutics reported Q3 2020 financial results, with total product revenues of $12.5 million, down 28.5% from $17.5 million in Q3 2019. The net loss increased to $4.9 million or $0.10 per share, compared to a $2.1 million loss in the previous year. However, Neos' ADHD prescription volumes show signs of recovery, with a 17.7% increase in prescriptions filled through its Neos RxConnect program, which now accounts for over 40% of total prescriptions. Adzenys XR-ODT and Cotempla XR-ODT outperformed the ADHD market, growing by 9.9% and 6.5%, respectively.
Neos Therapeutics, a pharmaceutical firm focused on central nervous system products, will report its Q3 2020 financial results on November 9, 2020, before the U.S. market opens. The management team will host a conference call at 8:30 a.m. ET to discuss the results and provide company updates. Access to the conference call is available via phone and a live audio webcast on their Investor Relations page. The call will also be available for replay for 30 days.
Neos Therapeutics, a pharmaceutical company focused on central nervous system products, announced that CEO Jerry McLaughlin will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 3:40 p.m. ET. The event will be accessible via a live webcast on the company's Investor Relations page. A replay will be available for 30 days post-event. Neos markets several ADHD treatments, including Adzenys XR-ODT and Cotempla XR-ODT, and is developing NT0502 for sialorrhea in patients with neurological conditions.
Neos Therapeutics (Nasdaq: NEOS) announced that CEO Jerry McLaughlin will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:30 p.m. ET. The presentation will provide an overview of the company's central nervous system-focused pharmaceutical products, including Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment. A live webcast will be available on their Investor Relations page, with a replay accessible for 30 days following the event.
Neos Therapeutics, a pharmaceutical company focused on central nervous system products, will report its first quarter 2020 financial results on May 11, 2020, after U.S. markets close. A conference call and audio webcast will follow at 5:00 p.m. ET, where management will discuss the results and provide updates. Interested parties can join the call via phone or through a live webcast on the company's Investor Relations page. Neos is known for its innovative microparticle delivery technology, offering products for ADHD treatment, including Adzenys XR-ODT and Cotempla XR-ODT.
